<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02049866</url>
  </required_header>
  <id_info>
    <org_study_id>AAAN0161</org_study_id>
    <secondary_id>1R01FD005114-01A2</secondary_id>
    <nct_id>NCT02049866</nct_id>
  </id_info>
  <brief_title>Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP</brief_title>
  <official_title>Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With Idiopathic Osteoporosis (IOP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elizabeth Shane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Creighton University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate antiresorptive therapy with denosumab&#xD;
      (Prolia) for prevention of bone loss after stopping teriparatide (TPTD) in premenopausal&#xD;
      women with idiopathic osteoporosis.&#xD;
&#xD;
      Premenopausal women who have received TPTD in the FDA Orphan Diseases Program-funded trial,&#xD;
      &quot;A Phase 2 Study of Teriparatide for the Treatment of Idiopathic Osteoporosis in&#xD;
      Premenopausal Women&quot; (NCT01440803) may be eligible to participate in the current study, a&#xD;
      36-month open-label pilot study of denosumab (ProliaÂ®, 60mg subcutaneous (SC) every 6&#xD;
      months).&#xD;
&#xD;
      The goals of the study are to estimate the effects of denosumab on central and peripheral, as&#xD;
      well as trabecular and cortical, bone mass and microstructure and to obtain preliminary data&#xD;
      to inform the design of a future randomized study. This study presents the first opportunity&#xD;
      to study the effects of denosumab after TPTD in this unique and severely affected group of&#xD;
      young women.&#xD;
&#xD;
      Funding Source: FDA Office of Orphan Products Development (OOPD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoporosis in premenopausal women with normal menstrual function and no specific cause is&#xD;
      termed idiopathic osteoporosis (IOP). IOP is a rare disease with an estimated prevalence of&#xD;
      &lt;200,000 affected premenopausal women in the United States.&#xD;
&#xD;
      Denosumab, a potent inhibitor of osteoclast-mediated bone resorption, leads to continuous&#xD;
      gains in both trabecular and cortical bone mineral density (BMD). Moreover, denosumab is not&#xD;
      retained in the skeleton, and may thus be preferable for use in young women who may be&#xD;
      contemplating future pregnancies. The investigators hypothesize that denosumab, initiated&#xD;
      after completion of two years of TPTD, will maintain or improve central and peripheral areal&#xD;
      and volumetric BMD, microstructure and stiffness in premenopausal women with IOP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 19, 2014</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Lumbar Spine Areal BMD by DXA</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Bone mineral density (BMD) will be measured with dual-energy X-ray absorptiometry (DXA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Lumbar Spine Areal BMD by DXA at 24 Months</measure>
    <time_frame>Baseline and 24 months</time_frame>
    <description>Bone mineral density (BMD) will be measured with dual-energy X-ray absorptiometry (DXA).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Adult Idiopathic Generalized Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months</description>
    <arm_group_label>Denosumab</arm_group_label>
    <other_name>Prolia</other_name>
    <other_name>Xgeva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All women completing NCT01440803 who remain without a disease or medication that&#xD;
             causes osteoporosis will be offered enrollment into this study.&#xD;
&#xD;
          -  (Premenopausal status is no longer be required for entry.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal insufficiency or liver disease: Creatinine, transaminase (AST)/alanine&#xD;
             transaminase (ALT) above upper limit of normal&#xD;
&#xD;
          -  Vitamin D deficiency: 25-hydroxyvitamin D (25-OHD) &lt;30 ng/mL&#xD;
&#xD;
          -  Pregnancy: urine pregnancy test must be negative&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Shane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adi Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Creighton University</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://columbiamedicine.org/divisions/Endo/index.shtml</url>
    <description>Columbia University, Dept of Medicine, Division of Endocrinology website</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 28, 2014</study_first_submitted>
  <study_first_submitted_qc>January 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2014</study_first_posted>
  <results_first_submitted>March 30, 2021</results_first_submitted>
  <results_first_submitted_qc>March 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 21, 2021</results_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Elizabeth Shane</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>premenopausal</keyword>
  <keyword>denosumab</keyword>
  <keyword>idiopathic</keyword>
  <keyword>Idiopathic Osteoporosis in Premenopausal Women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT02049866/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Denosumab</title>
          <description>Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months.&#xD;
Denosumab: Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Denosumab</title>
          <description>Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months.&#xD;
Denosumab: Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Lumbar Spine Areal BMD by DXA</title>
        <description>Bone mineral density (BMD) will be measured with dual-energy X-ray absorptiometry (DXA).</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>33 participants completed baseline but 1 participant withdrew from the study before the 12 month visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months.&#xD;
Denosumab: Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Lumbar Spine Areal BMD by DXA</title>
          <description>Bone mineral density (BMD) will be measured with dual-energy X-ray absorptiometry (DXA).</description>
          <population>33 participants completed baseline but 1 participant withdrew from the study before the 12 month visit.</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Lumbar Spine Areal BMD by DXA at 24 Months</title>
        <description>Bone mineral density (BMD) will be measured with dual-energy X-ray absorptiometry (DXA).</description>
        <time_frame>Baseline and 24 months</time_frame>
        <posting_date>03/2023</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for 1 year (from baseline to 12 month study participation).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Denosumab</title>
          <description>Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months.&#xD;
Denosumab: Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Low Energy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <description>Nonvertebral fragility fracture</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Muscle cramps</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain in thighs, hips, or groin</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Numbness and/or tingling</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hair loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Redness</sub_title>
                <description>Redness at injection site reaction</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Injection site reaction</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mariana Bucovsky</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-7225</phone>
      <email>mb3523@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

